title: Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location.
abstract: Approximately 22,000 cases of ovarian cancer occur each year in the United States, and likely fewer than 2000 cases of mucinous ovarian cancers. Although 90% of patients with mucinous ovarian cancer present with stage I disease and have curative surgeries, advanced-stage disease is known to have a poor response to standard platinum- and taxane-based chemotherapy. Despite limited enthusiasm, standard chemotherapy is still recommended for most patients with advanced-stage mucinous malignancies of the ovary. This report presents an unusual case of a woman with HER2-positive metastatic mucinous carcinoma of the ovary treated with chemotherapy regimens typically used for colorectal malignancies, followed by epidermal growth factor receptor-targeted therapies.
authors.affiliation: From Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA. Angela.Jain@fccc.edu
authors.forename: Angela
authors.initials: A
authors.lastname: Jain
authors.forename: Paula D
authors.initials: PD
authors.lastname: Ryan
authors.forename: Michael V
authors.initials: MV
authors.lastname: Seiden
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D014408:Biomarkers, Tumor / Q000032:analysis*; D001932:Brain Neoplasms / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery; D018282:Cystadenocarcinoma, Mucinous / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D000077341:Lapatinib; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011799:Quinazolines / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D000068878:Trastuzumab; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; D042442:Vascular Endothelial Growth Factors; C512478:EGFR protein, human; C508053:ERBB2 protein, human